Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment

World Journal of Gastroenterology

Volumn 20, Issue 36, 2014, Pages 12781-12808

  Testerman, Traci L ^a   Morris, James ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Autoimmune; CagA; Cancer; Diagnosis; Enterohepatic; Extragastric; Inflammation; Pathogenesis; Treatment; Virulence factor

Indexed keywords

ANTIBIOTIC AGENT; CYTOTOXIN; GAMMA GLUTAMYLTRANSFERASE; HOST FACTOR; NEUTROPHIL ACTIVATING PROTEIN; OUTER MEMBRANE PROTEIN; PROTEIN BABA; PROTEIN SABA; SIALOADHESIN; UNCLASSIFIED DRUG; VACUOLATING TOXIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ALLERGIC DISEASE; BACTERIAL COLONIZATION; COLORECTAL CANCER; COST OF ILLNESS; DEVELOPED COUNTRY; DYSPEPSIA; ESOPHAGUS DISEASE; GASTRITIS; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; INCIDENCE; INFECTION RATE; IRON DEFICIENCY ANEMIA; LARYNX CANCER; LYMPHOMA; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PHARYNX CANCER; PREVALENCE; REVIEW; RISK FACTOR; SALVAGE THERAPY; STOMACH CANCER; STOMACH ULCER; TREATMENT INDICATION; UNITED STATES; ANIMAL; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; HELICOBACTER INFECTIONS; HOST PATHOGEN INTERACTION; MICROBIOLOGY; PATHOGENICITY; PREDICTIVE VALUE; STOMACH DISEASES; TREATMENT OUTCOME; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS; INCIDENCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; STOMACH DISEASES; TREATMENT OUTCOME; VIRULENCE;

EID: 84925268782     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i36.12781     Document Type: Review

References (316)

1. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, Falush D, Stamer C, Prugnolle F, van der Merwe SW, Yamaoka Y, Graham DY, Perez-Trallero E, Wadstrom T, Suerbaum S, Achtman M. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007; 445: 915-918 [PMID: 17287725 DOI: 10.1038/nature05562]
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315 [PMID: 6145023 DOI: 10.1016/S0140-6736(84)91816-6]
3. Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter Pylori associated global gastric cancer burden. Front Biosci (Landmark Ed) 2009; 14: 1490-1504 [PMID: 19273142 DOI: 10.2741/3320]
4. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15: 460-466 [PMID: 21083752 DOI: 10.1111/j.1523-5378.2010.00788.x]
5. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10 Suppl 1: 40-46 [PMID: 16178970]
6. Suzuki R, Shiota S, Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 2012; 12: 203-213 [PMID: 22197766 DOI: 10.1016/j.meegid.2011.12.002]
7. Mishra S. Is Helicobacter pylori good or bad? Eur J Clin Microbiol Infect Dis 2013; 32: 301-304 [PMID: 23132690 DOI: 10.1007/s10096-012-1773-9]
8. Lertsethtakarn P, Ottemann KM, Hendrixson DR. Motility and chemotaxis in Campylobacter and Helicobacter. Annu Rev Microbiol 2011; 65: 389-410 [PMID: 21939377 DOI: 10.1146/annurev-micro-090110-102908]
9. McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother 2011; 55: 2897-2904 [PMID: 21464244 DOI: 10.1128/AAC.00016-11]
10. Wang HJ, Cheng WC, Cheng HH, Lai CH, Wang WC. Helicobacter pylori cholesteryl glucosides interfere with host membrane phase and affect type IV secretion system function during infection in AGS cells. Mol Microbiol 2012; 83: 67-84 [PMID: 22053852 DOI: 10.1111/j.1365-2958.2011.07910.x]
11. Beigier-Bompadre M, Moos V, Belogolova E, Allers K, Schneider T, Churin Y, Ignatius R, Meyer TF, Aebischer T. Modulation of the CD4+ T-cell response by Helicobacter pylori depends on known virulence factors and bacterial cholesterol and cholesterol α-glucoside content. J Infect Dis 2011; 204: 1339-1348 [PMID: 21921201 DOI: 10.1093/infdis/jir547]
12. Backert S, Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2011; 16 Suppl 1: 19-25 [PMID: 21896081 DOI: 10.1111/j.1523-5378.2011.00876.x]
13. Olofsson A, Vallström A, Petzold K, Tegtmeyer N, Schleucher J, Carlsson S, Haas R, Backert S, Wai SN, Gröbner G, Arnqvist A. Biochemical and functional characterization of Helicobacter pylori vesicles. Mol Microbiol 2010; 77: 1539-1555 [PMID: 20659286 DOI: 10.1111/j.1365-2958.2010.07307.x]
14. Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett 2011; 305: 228-238 [PMID: 20692762 DOI: 10.1016/j.canlet.2010.07.014]
15. Tegtmeyer N, Hartig R, Delahay RM, Rohde M, Brandt S, Conradi J, Takahashi S, Smolka AJ, Sewald N, Backert S. A small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation. J Biol Chem 2010; 285: 23515-23526 [PMID: 20507990 DOI: 10.1074/jbc.M109.096214]
16. Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 2011; 278: 1190-1202 [PMID: 21352489 DOI: 10.1111/j.1742-4658.2011.08035.x]
17. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010; 7: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]
18. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683-686 [PMID: 11743164 DOI: 10.1126/science.1067147]
19. Bourzac KM, Guillemin K. Helicobacter pylori-host cell interactions mediated by type IV secretion. Cell Microbiol 2005; 7: 911-919 [PMID: 15953024]
20. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430-1434 [PMID: 12775840]
21. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323 [PMID: 18166359 DOI: 10.1053/j.gastro.2007.11.009]
22. Fischer W, Prassl S, Haas R. Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori. Curr Top Microbiol Immunol 2009; 337: 129-171 [PMID: 19812982 DOI: 10.1007/978-3-642-01846-6-5]
23. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 1863-1873 [PMID: 19457415 DOI: 10.1053/j.gastro.2009.01.073]
24. Tanaka H, Yoshida M, Nishiumi S, Ohnishi N, Kobayashi K, Yamamoto K, Fujita T, Hatakeyama M, Azuma T. The CagA protein of Helicobacter pylori suppresses the functions of dendritic cell in mice. Arch Biochem Biophys 2010; 498: 35-42 [PMID: 20363211 DOI: 10.1016/j.abb.2010.03.021]
25. Stein M, Bagnoli F, Halenbeck R, Rappuoli R, Fantl WJ, Covacci A. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol 2002; 43: 971-980 [PMID: 11929545]
26. Jones KR, Joo YM, Jang S, Yoo YJ, Lee HS, Chung IS, Olsen CH, Whitmire JM, Merrell DS, Cha JH. Polymorphism in the CagA EPIYA motif impacts development of gastric cancer. J Clin Microbiol 2009; 47: 959-968 [PMID: 19158258 DOI: 10.1128/JCM.02330-08]
27. Lee IO, Kim JH, Choi YJ, Pillinger MH, Kim SY, Blaser MJ, Lee YC. Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. J Biol Chem 2010; 285: 16042-16050 [PMID: 20348091 DOI: 10.1074/jbc.M110.111054]
28. Kim IJ, Blanke SR. Remodeling the host environment: modulation of the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA). Front Cell Infect Microbiol 2012; 2: 37 [PMID: 22919629 DOI: 10.3389/fcimb.2012.00037]
29. Sewald X, Fischer W, Haas R. Sticky socks: Helicobacter pylori VacA takes shape. Trends Microbiol 2008; 16: 89-92 [PMID: 18280164 DOI: 10.1016/j.tim.2008.01.001]
30. Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 2005; 3: 320-332 [PMID: 15759043 DOI: 10.1038/nrmicro1095]
31. Palframan SL, Kwok T, Gabriel K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol 2012; 2: 92 [PMID: 22919683 DOI: 10.3389/fcimb.2012.00092]
32. Papini E, Satin B, Norais N, de Bernard M, Telford JL, Rappuoli R, Montecucco C. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin. J Clin Invest 1998; 102: 813-820 [PMID: 9710450 DOI: 10.1172/JCI2764]
33. Chung C, Olivares A, Torres E, Yilmaz O, Cohen H, Perez-Perez G. Diversity of VacA intermediate region among Helicobacter pylori strains from several regions of the world. J Clin Microbiol 2010; 48: 690-696 [PMID: 20053862 DOI: 10.1128/JCM.01815-09]
34. Lu H, Yamaoka Y, Graham DY. Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 2005; 21: 653-659 [PMID: 16220040 DOI: 10.1097/01.mog.0000181711.04529.d5]
35. Toller IM, Neelsen KJ, Steger M, Hartung ML, Hottiger MO, Stucki M, Kalali B, Gerhard M, Sartori AA, Lopes M, Müller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci USA 2011; 108: 14944-14949 [PMID: 21896770 DOI: 10.1073/pnas.1100959108]
36. Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, Borén T, Haas R, Sasakawa C, Mimuro H. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem 2011; 286: 25256-25264 [PMID: 21596743 DOI: 10.1074/jbc.M111.233601]
37. Borén T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262: 1892-1895 [PMID: 8018146 DOI: 10.1126/science.8018146]
38. Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-578 [PMID: 12142529]
39. Yamaoka Y. Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease. J Infect Dev Ctries 2008; 2: 174-181 [PMID: 19738347]
40. Senkovich OA, Yin J, Ekshyyan V, Conant C, Traylor J, Adegboyega P, McGee DJ, Rhoads RE, Slepenkov S, Testerman TL. Helicobacter pylori AlpA and AlpB bind host laminin and influence gastric inflammation in gerbils. Infect Immun 2011; 79: 3106-3116 [PMID: 21576328 DOI: 10.1128/IAI.01275-10]
41. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci USA 2000; 97: 7533-7538 [PMID: 10852959 DOI: 10.1073/pnas.130079797]
42. Backert S, Clyne M, Tegtmeyer N. Molecular mechanisms of gastric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal 2011; 9: 28 [PMID: 22044679 DOI: 10.1186/1478-811X-9-28]
43. Franco AT, Johnston E, Krishna U, Yamaoka Y, Israel DA, Nagy TA, Wroblewski LE, Piazuelo MB, Correa P, Peek RM. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res 2008; 68: 379-387 [PMID: 18199531]
44. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153 [PMID: 20488613 DOI: 10.1016/j.canlet.2010.04.025]
45. Evans DJ, Evans DG, Takemura T, Nakano H, Lampert HC, Graham DY, Granger DN, Kvietys PR. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995; 63: 2213-2220 [PMID: 7768601]
46. Smith JL. The physiological role of ferritin-like compounds in bacteria. Crit Rev Microbiol 2004; 30: 173-185 [PMID: 15490969 DOI: 10.1080/10408410490435151]
47. de Bernard M, D'Elios MM. The immune modulating activity of the Helicobacter pylori HP-NAP: Friend or foe? Toxicon 2010; 56: 1186-1192 [PMID: 19818802 DOI: 10.1016/j.toxicon.2009.09.020]
48. Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri A, D'Elios MM, Del Prete G, de Bernard M. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006; 116: 1092-1101 [PMID: 16543949 DOI: 10.1172/JCI27177]
49. Montemurro P, Barbuti G, Dundon WG, Del Giudice G, Rappuoli R, Colucci M, De Rinaldis P, Montecucco C, Semeraro N, Papini E. Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J Infect Dis 2001; 183: 1055-1062 [PMID: 11237830 DOI: 10.1086/319280]
50. Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther 2013; 21: 2008-2018 [PMID: 23817216 DOI: 10.1038/mt.2013.153]
51. Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M, Pagano F, D'Elios MM, de Bernard M. HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother 2012; 61: 31-40 [PMID: 21833592 DOI: 10.1007/s00262-011-1087-2]
52. Amedei A, Codolo G, Del Prete G, de Bernard M, D'Elios MM. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy 2010; 3: 139-147 [PMID: 21437048 DOI: 10.2147/JAA.S8971]
53. Codolo G, Mazzi P, Amedei A, Del Prete G, Berton G, D'Elios MM, de Bernard M. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol 2008; 10: 2355-2363 [PMID: 18671823 DOI: 10.1111/j.1462-5822.2008.01217.x]
54. Kountouras J, Zavos C, Gavalas E, Deretzi G, Tsona A, Katsinelos P, Grigoriadis S, Pilpilidis I, Tzilves D, Vardaka E, Mantzoukis K, Polyzos SA. A rebuttal to the potential antitumour benefit of Helicobacter pylori-induced neutrophil-activating protein. Cancer Immunol Immunother 2012; 61: 445-46; discussion 445-46; [PMID: 22065048 DOI: 10.1007/s00262-011-1142-z]
55. Chevalier C, Thiberge JM, Ferrero RL, Labigne A. Essential role of Helicobacter pylori gamma-glutamyltranspeptidase for the colonization of the gastric mucosa of mice. Mol Microbiol 1999; 31: 1359-1372 [PMID: 10200957]
56. Gong M, Ling SS, Lui SY, Yeoh KG, Ho B. Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology 2010; 139: 564-573 [PMID: 20347814 DOI: 10.1053/j.gastro.2010.03.050]
57. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C, Müller A. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA 2013; 110: 3047-3052 [PMID: 23382221 DOI: 10.1073/pnas.1211248110]
58. Flahou B, Haesebrouck F, Chiers K, Van Deun K, De Smet L, Devreese B, Vandenberghe I, Favoreel H, Smet A, Pasmans F, D'Herde K, Ducatelle R. Gastric epithelial cell death caused by Helicobacter suis and Helicobacter pylori γ-glutamyl transpeptidase is mainly glutathione degradation-dependent. Cell Microbiol 2011; 13: 1933-1955 [PMID: 21899697 DOI: 10.1111/j.1462-5822.2011.01682.x]
59. Testerman TL, Conn PB, Mobley HL, McGee DJ. Nutritional requirements and antibiotic resistance patterns of Helicobacter species in chemically defined media. J Clin Microbiol 2006; 44: 1650-1658 [PMID: 16672389]
60. Senkovich O, Ceaser S, McGee DJ, Testerman TL. Unique host iron utilization mechanisms of Helicobacter pylori revealed with iron-deficient chemically defined media. Infect Immun 2010; 78: 1841-1849 [PMID: 20176792]
61. Semino-Mora C, Testerman TL, Liu H, Whitmire JM, Studeman K, Jia Y, McAvoy TJ, Francis J, Nieroda C, Sardi A, Merrell DS, Dubois A. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. Clin Cancer Res 2013; 19: 3966-3976 [PMID: 23743566 DOI: 10.1158/1078-0432.CCR-13-0616]
62. Zhang S, Guo Y, Ma Y, Teng Y. Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J (Engl) 2008; 121: 946-951 [PMID: 18706211]
63. Hirsch C, Tegtmeyer N, Rohde M, Rowland M, Oyarzabal OA, Backert S. Live Helicobacter pylori in the root canal of endodontic-infected deciduous teeth. J Gastroenterol 2012; 47: 936-940 [PMID: 22722905 DOI: 10.1007/s00535-012-0618-8]
64. Sudhakar U, Anusuya CN, Ramakrishnan T, Vijayalakshmi R. Isolation of Helicobacter pylori from dental plaque: A microbiological study. J Indian Soc Periodontol 2008; 12: 67-72 [PMID: 20142948 DOI: 10.4103/0972-124X.44098]
65. Lukeš P, Pavlík E, Potužníková B, Plzák J, Nártová E, Doseděl J, Katra R, Sterzl I, Betka J, Astl J. Comparison of Helicobacter pylori genotypes obtained from the oropharynx and stomach of the same individuals - a pilot study. Prague Med Rep 2012; 113: 231-239 [PMID: 22980564]
66. Morales-Espinosa R, Fernandez-Presas A, Gonzalez-Valencia G, Flores-Hernandez S, Delgado-Sapien G, Mendez-Sanchez JL, Sanchez-Quezada E, Muñoz-Pérez L, Leon-Aguilar R, Hernandez-Guerrero J, Cravioto A. Helicobacter pylori in the oral cavity is associated with gastroesophageal disease. Oral Microbiol Immunol 2009; 24: 464-468 [PMID: 19832798 DOI: 10.1111/j.1399-302X.2009.00541.x]
67. Liu Y, Yue H, Li A, Wang J, Jiang B, Zhang Y, Bai Y. An epidemiologic study on the correlation between oral Helicobacter pylori and gastric H. pylori. Curr Microbiol 2009; 58: 449-453 [PMID: 19139956 DOI: 10.1007/s00284-008-9341-3]
68. Chaudhry S, Khan AA, Butt AK, Idrees M, Izhar M, Iqbal HA. Helicobacter pylori in dental plaque; is it related to brushing frequency, plaque load and oral health status? J Coll Physicians Surg Pak 2011; 21: 589-592 [PMID: 22015117 DOI: 10.2011/JCPSP.589592]
69. Namiot DB, Leszczyńska K, Namiot Z, Chilewicz M, Bucki R, Kemona A. The occurrence of Helicobacter pylori antigens in dental plaque; an association with oral health status and oral hygiene practices. Adv Med Sci 2010; 55: 167-171 [PMID: 20934966 DOI: 10.2478/v10039-010-0032-5]
70. Bouziane A, Ahid S, Abouqal R, Ennibi O. Effect of periodontal therapy on prevention of gastric Helicobacter pylori recurrence: a systematic review and meta-analysis. J Clin Periodontol 2012; 39: 1166-1173 [PMID: 23151293 DOI: 10.1111/jcpe.12015]
71. Song HY, Li Y. Can eradication rate of gastric Helicobacter pylori be improved by killing oral Helicobacter pylori? World J Gastroenterol 2013; 19: 6645-6650 [PMID: 24151394 DOI: 10.3748/wjg.v19.i39.6645]
72. O'Rourke JL, Grehan M, Lee A. Non-pylori Helicobacter species in humans. Gut 2001; 49: 601-606 [PMID: 11600455]
73. Flahou B, Haesebrouck F, Smet A, Yonezawa H, Osaki T, Kamiya S. Gastric and enterohepatic non-Helicobacter pylori Helicobacters. Helicobacter 2013; 18 Suppl 1: 66-72 [PMID: 24011248 DOI: 10.1111/hel.12072]
74. Zhou D, Guan WB, Wang JD, Zhang Y, Gong W, Quan ZW. A comparative study of clinicopathological features between chronic cholecystitis patients with and without Helicobacter pylori infection in gallbladder mucosa. PLoS One 2013; 8: e70265 [PMID: 23936177 DOI: 10.1371/journal.pone.0070265]
75. Zavos C, Kountouras J, Sakkias G, Venizelos I, Deretzi G, Arapoglou S. Histological presence of Helicobacter pylori bacteria in the trabeculum and iris of patients with primary open-angle glaucoma. Ophthalmic Res 2012; 47: 150-156 [PMID: 22094712 DOI: 10.1159/000330053]
76. Joo M, Kwak JE, Chang SH, Kim H, Chi JG, Kim KA, Yang JH, Lee JS, Moon YS, Kim KM. Helicobacter heilmannii-associated gastritis: clinicopathologic findings and comparison with Helicobacter pylori-associated gastritis. J Korean Med Sci 2007; 22: 63-69 [PMID: 17297253 DOI: 10.3346/jkms.2007.22.1.63]
77. Solnick JV. Clinical significance of Helicobacter species other than Helicobacter pylori. Clin Infect Dis 2003; 36: 349-354 [PMID: 12539077 DOI: 10.1086/346038]
78. Thomson JM, Hansen R, Berry SH, Hope ME, Murray GI, Mukhopadhya I, McLean MH, Shen Z, Fox JG, El-Omar E, Hold GL. Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? PLoS One 2011; 6: e17184 [PMID: 21383845 DOI: 10.1371/journal.pone.0017184]
79. Hansen R, Thomson JM, Fox JG, El-Omar EM, Hold GL. Could Helicobacter organisms cause inflammatory bowel disease? FEMS Immunol Med Microbiol 2011; 61: 1-14 [PMID: 20955468 DOI: 10.1111/j.1574-695X.2010.00744.x]
80. Xu S, Wan X, Zheng X, Zhou Y, Song Z, Cheng M, Du Y, Hou X. Symptom improvement after helicobacter pylori eradication in patients with functional dyspepsia-A multicenter, randomized, prospective cohort study. Int J Clin Exp Med 2013; 6: 747-756 [PMID: 24179567]
81. Selgrad M, Kandulski A, Malfertheiner P. Dyspepsia and Helicobacter pylori. Dig Dis 2008; 26: 210-214 [PMID: 18463437 DOI: 10.1159/000121348]
82. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]
83. McColl KE, el-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998; 54: 121-138 [PMID: 9604437]
84. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007; 21: 281-297 [PMID: 17382277 DOI: 10.1016/j.bpg.2007.02.002]
85. Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 2009; 60: 3-21 [PMID: 19826177]
86. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]
87. Musumba C, Jorgensen A, Sutton L, Van Eker D, Moorcroft J, Hopkins M, Pritchard DM, Pirmohamed M. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012; 36: 48-56 [PMID: 22554233 DOI: 10.1111/j.1365-2036.2012.05118.x]
88. Tang CL, Ye F, Liu W, Pan XL, Qian J, Zhang GX. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter 2012; 17: 286-296 [PMID: 22759329 DOI: 10.1111/j.1523-5378.2012.00942.x]
89. Overmier JB, Murison R. Restoring psychology's role in peptic ulcer. Appl Psychol Health Well Being 2013; 5: 5-27 [PMID: 23457084 DOI: 10.1111/j.1758-0854.2012.01076.x]
90. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L, Perez-Perez GI, Hatakeyama M, Whitehead R, Gaus K, O'Brien DP, Romero-Gallo J, Peek RM. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA 2005; 102: 10646-10651 [PMID: 16027366 DOI: 10.1073/pnas.0504927102]
91. Zagari RM, Bazzoli F. Gastric cancer: who is at risk? Dig Dis 2004; 22: 302-305 [PMID: 15812151 DOI: 10.1159/000083590]
92. Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. J Clin Pathol 2003; 56: 287-291 [PMID: 12663641]
93. Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehlke S, Classen M, Prinz C. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 1999; 96: 12778-12783 [PMID: 10535999]
94. Yamaoka Y, Ojo O, Fujimoto S, Odenbreit S, Haas R, Gutierrez O, El-Zimaity HM, Reddy R, Arnqvist A, Graham DY. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut 2006; 55: 775-781 [PMID: 16322107]
95. Batista SA, Rocha GA, Rocha AM, Saraiva IE, Cabral MM, Oliveira RC, Queiroz DM. Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. BMC Microbiol 2011; 11: 61 [PMID: 21435255 DOI: 10.1186/1471-2180-11-61]
96. Wroblewski LE, Peek RM. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am 2013; 42: 285-298 [PMID: 23639641 DOI: 10.1016/j.gtc.2013.01.006]
97. Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006; 208: 233-248 [PMID: 16362989 DOI: 10.1002/path.1868]
98. Piazuelo MB, Epplein M, Correa P. Gastric cancer: an infectious disease. Infect Dis Clin North Am 2010; 24: 853-69, vii [PMID: 20937454 DOI: 10.1016/j.idc.2010.07.010]
99. Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M, Shinomura Y. Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion 2011; 83: 241-249 [PMID: 21273772 DOI: 10.1159/000320453]
100. Oguri A, Ohmiya N, Taguchi A, Itoh A, Hirooka Y, Niwa Y, Maeda O, Ando T, Goto H. Rugal hyperplastic gastritis increases the risk of gastric carcinoma, especially diffuse and p53-independent subtypes. Eur J Gastroenterol Hepatol 2007; 19: 561-566 [PMID: 17556902 DOI: 10.1097/MEG.0b013e32811ec056]
101. Nasri S, More H, Graziano F, Ruzzo A, Wilson E, Dunbier A, McKinney C, Merriman T, Guilford P, Magnani M, Humar B. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population. BMC Cancer 2008; 8: 138 [PMID: 18482459 DOI: 10.1186/1471-2407-8-138]
102. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176 [PMID: 1682595 DOI: 10.1016/0140-6736(91)92035-Z]
103. Lehours P, Ménard A, Dupouy S, Bergey B, Richy F, Zerbib F, Ruskoné-Fourmestraux A, Delchier JC, Mégraud F. Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun 2004; 72: 880-888 [PMID: 14742532]
104. Kuo SH, Chen LT, Lin CW, Wu MS, Hsu PN, Tsai HJ, Chu CY, Tzeng YS, Wang HP, Yeh KH, Cheng AL. Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance. Blood Cancer J 2013; 3: e125 [PMID: 23852160 DOI: 10.1038/bcj.2013.22]
105. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-3044 [PMID: 16397126 DOI: 10.1182/blood-2005-09-3679]
106. Lenze D, Berg E, Volkmer-Engert R, Weiser AA, Greiner A, Knörr-Wittmann C, Anagnostopoulos I, Stein H, Hummel M. Influence of antigen on the development of MALT lymphoma. Blood 2006; 107: 1141-1148 [PMID: 16204314 DOI: 10.1182/blood-2005-04-1722]
107. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110 [PMID: 19631287 DOI: 10.1016/j.cgh.2009.07.017]
108. Raderer M, Streubel B, Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618 [PMID: 16299027 DOI: 10.1136/gut.2005.083022]
109. Iwai H, Nakamichi N, Nakae K, Konishi M, Inaba M, Hoshino S, Baba S, Amakawa R. Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication. Laryngoscope 2009; 119: 1491-1494 [PMID: 19504556 DOI: 10.1002/lary.20258]
110. Hong SN, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, Lee SY, Cheon YK, Sung IK, Park HS, Shim CS. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci 2012; 57: 2184-2194 [PMID: 22669208 DOI: 10.1007/s10620-012-2245-x]
111. Wang F, Sun MY, Shi SL, Lv ZS. Helicobacter pylori infection and normal colorectal mucosa-adenomatous polypadenocarcinoma sequence: a meta-analysis of 27 case-control studies. Colorectal Dis 2014; 16: 246-252 [PMID: 23692360 DOI: 10.1111/codi.12290]
112. Rokkas T, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Koukoulis G. The relationship of Helicobacter pylori infection and colon neoplasia, on the basis of meta-analysis. Eur J Gastroenterol Hepatol 2013; 25: 1286-1294 [PMID: 23820245 DOI: 10.1097/MEG.0b013e328363d3cd]
113. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013; 108: 208-215 [PMID: 23208272 DOI: 10.1038/ajg.2012.407]
114. Shmuely H, Melzer E, Braverman M, Domniz N, Yahav J. Helicobacter pylori infection is associated with advanced colorectal neoplasia. Scand J Gastroenterol 2014; 49: 35-42 [PMID: 24164483 DOI: 10.3109/00365521.2013.848468]
115. Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg 2008; 45: 527-575 [PMID: 18590843 DOI: 10.1067/j.cpsurg.2008.04.003]
116. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH. Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol 2006; 32: 764-766 [PMID: 16765563 DOI: 10.1016/j.ejso.2006.04.009]
117. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol 2008; 15: 1414-1423 [PMID: 18299935 DOI: 10.1245/s10434-007-9778-9]
118. Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis 2013; 8: 105 [PMID: 23844722 DOI: 10.1186/1750-1172-8-105]
119. Deutsch AJ, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, Schaider H, Neumeister P. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol 2013; 26: 182-194 [PMID: 22936065 DOI: 10.1038/modpathol.2012.134]
120. Cavanna L, Pagani R, Seghini P, Zangrandi A, Paties C. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol 2008; 6: 35 [PMID: 18353178 DOI: 10.1186/1477-7819-6-35]
121. Inaba K, Kushima R, Murakami N, Kuroda Y, Harada K, Kitaguchi M, Yoshio K, Sekii S, Takahashi K, Morota M, Mayahara H, Ito Y, Sumi M, Uno T, Itami J. Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma. BMC Cancer 2013; 13: 499 [PMID: 24159918 DOI: 10.1186/1471-2407-13-499]
122. De Sanctis V, Marignani M, Angeletti S, Assisi D, Armosini V, Valeriani M, Minniti G, Cox MC, Ruco L, Enrici RM. Anti-Helicobacter pylori therapy in primary MALT lymphoma of rectum. Tumori 2012; 98: e105-e110 [PMID: 23052174 DOI: 10.1700/1146.12654]
123. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009; 114: 501-510 [PMID: 19372259 DOI: 10.1182/blood-2008-12-195453]
124. Decaudin D, Ferroni A, Vincent-Salomon A, Beldjord K, Validire P, de Cremoux P, Validire P, Plancher C, Mathiot C, Macintyre E, Asselain B, Girodet J, Mal F, Brousse N, Beretti JL, Dendale R, Lumbroso-Le Rouic L, Hermine O, Lecuit M. Ocular adnexal lymphoma and Helicobacter pylori gastric infection. Am J Hematol 2010; 85: 645-649 [PMID: 20645425 DOI: 10.1002/ajh.21765]
125. Chan CC, Shen D, Mochizuki M, Gonzales JA, Yuen HK, Guex-Crosier Y, Lehoang P. Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma. Trans Am Ophthalmol Soc 2006; 104: 62-70 [PMID: 17471326]
126. Aygenc E, Selcuk A, Celikkanat S, Ozbek C, Ozdem C. The role of Helicobacter pylori infection in the cause of squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg 2001; 125: 520-521 [PMID: 11700453]
127. Gong H, Shi Y, Zhou L, Tao L, Shi Y, Cao W, Cheng L. Helicobacter pylori infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma. Clin Transl Oncol 2012; 14: 905-910 [PMID: 22855167 DOI: 10.1007/s12094-012-0879-y]
128. Shi Y, Gong H, Zhou L, Tao L, Shi Y, Cao W, Cheng L. Association between Helicobacter pylori infection and laryngeal squamous cell carcinoma in a Chinese male population. ORL J Otorhinolaryngol Relat Spec 2011; 73: 295-300 [PMID: 21952073 DOI: 10.1159/000330955]
129. Burduk PK. Association between infection of virulence cagA gene Helicobacter pylori and laryngeal squamous cell carcinoma. Med Sci Monit 2013; 19: 584-591 [PMID: 23860397 DOI: 10.12659/MSM.889011]
130. Guilemany JM, Langdon C, Ballesteros F, Blanch JL. Prognostic significance and association of Helicobacter pylori infection in pharyngolaryngeal cancer. Eur Arch Otorhinolaryngol 2014; 271: 2539-2543 [PMID: 24193293 DOI: 10.1007/s00405-013-2794-4]
131. Masoud N, Manouchehr K, Najmeh D, Monireh H. Lack of association between Helicobacter pylori and laryngeal carcinoma. Asian Pac J Cancer Prev 2008; 9: 81-82 [PMID: 18439080]
132. Kizilay A, Saydam L, Aydin A, Kalcioglu MT, Ozturan O, Aydin NE. Histopathologic examination for Helicobacter pylori as a possible etiopathogenic factor in laryngeal carcinoma. Chemotherapy 2006; 52: 80-82 [PMID: 16498240 DOI: 10.1159/000091727]
133. Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, Wu L, Lin H, Chen Z, Zhu C, Lu L, Sun X, Rong L, Jiang Y, Sun D, Zhong L, Xiong P. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010; 86: 272-278 [PMID: 20448223 DOI: 10.1136/pgmj.2009.089987]
134. Yuan W, Li Yumin D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665-676 [PMID: 20201716 DOI: 10.3109/00365521003663670]
135. Yokota S, Toita N, Yamamoto S, Fujii N, Konno M. Positive relationship between a polymorphism in Helicobacter pylori neutrophil-activating protein a gene and iron-deficiency anemia. Helicobacter 2013; 18: 112-116 [PMID: 23067298 DOI: 10.1111/hel.12011]
136. Choe YH, Oh YJ, Lee NG, Imoto I, Adachi Y, Toyoda N, Gabazza EC. Lactoferrin sequestration and its contribution to iron-deficiency anemia in Helicobacter pylori-infected gastric mucosa. J Gastroenterol Hepatol 2003; 18: 980-985 [PMID: 12859729 DOI: 10.1046/j.1440-1746.2003.03098.x]
137. Afifi MT, Abd El-Aziz HK, Hamed NA, Barghash NA, Abdo A, Gamal M. Role of Helicobacter pylori in refractory iron deficiency anaemia. Br J Biomed Sci 2009; 66: 133-136 [PMID: 19839223]
138. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, Ikeda Y, Kuwana M. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008; 118: 2939-2949 [PMID: 18654664 DOI: 10.1172/JCI34496]
139. Sato R, Murakami K, Okimoto T, Watanabe K, Kodama M, Fujioka T. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol 2011; 46: 991-997 [PMID: 21594563 DOI: 10.1007/s00535-011-0416-8]
140. Satoh T, Pandey JP, Okazaki Y, Asahi A, Kawakami Y, Ikeda Y, Kuwana M. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens 2009; 73: 353-357 [PMID: 19317746 DOI: 10.1111/j.1399-0039.2009.01214.x]
141. Argenziano G, Donnarumma G, Iovene MR, Arnese P, Baldassarre MA, Baroni A. Incidence of anti-Helicobacter pylori and anti-CagA antibodies in rosacea patients. Int J Dermatol 2003; 42: 601-604 [PMID: 12890101 DOI: 10.1046/j.1365-4362.2003.01817.x]
142. El-Khalawany M, Mahmoud A, Mosbeh AS, A B D Alsalam F, Ghonaim N, Abou-Bakr A. Role of Helicobacter pylori in common rosacea subtypes: a genotypic comparative study of Egyptian patients. J Dermatol 2012; 39: 989-995 [PMID: 23039081 DOI: 10.1111/j.1346-8138.2012.01675.x]
143. Daković Z, Vesić S, Vuković J, Milenković S, Janković-Terzić K, Dukić S, Pavlović MD. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: a case series. Acta Dermatovenerol Alp Pannonica Adriat 2007; 16: 83-86 [PMID: 17992465]
144. Baykal C, Buyukbabani N, Akinturk S, Saglik E. Prurigo pigmentosa: not an uncommon disease in the Turkish population. Int J Dermatol 2006; 45: 1164-1168 [PMID: 17040430 DOI: 10.1111/j.1365-4632.2006.02857.x]
145. Akashi R, Ishiguro N, Shimizu S, Kawashima M. Clinical study of the relationship between Helicobacter pylori and chronic urticaria and prurigo chronica multiformis: effectiveness of eradication therapy for Helicobacter pylori. J Dermatol 2011; 38: 761-766 [PMID: 21352335 DOI: 10.1111/j.1346-8138.2010.01106.x]
146. Shiotani A, Sakurane M, Furukawa F. Helicobacter pylori-positive patients with pruritic skin diseases are at increased risk for gastric cancer. Aliment Pharmacol Ther 2004; 20 Suppl 1: 80-84 [PMID: 15298610 DOI: 10.1111/j.1365-2036.2004.01977.x]
147. Shiotani A, Okada K, Yanaoka K, Itoh H, Nishioka S, Sakurane M, Matsunaka M. Beneficial effect of Helicobacter pylori eradication in dermatologic diseases. Helicobacter 2001; 6: 60-65 [PMID: 11328367 DOI: 10.1046/j.1523-5378.2001.00009.x]
148. Missall TA, Pruden S, Nelson C, Fohn L, Vidal CI, Hurley MY. Identification of Helicobacter pylori in skin biopsy of prurigo pigmentosa. Am J Dermatopathol 2012; 34: 446-448 [PMID: 22197863 DOI: 10.1097/DAD.0b013e318231ae4a]
149. Federman DG, Kirsner RS, Moriarty JP, Concato J. The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003; 49: 861-864 [PMID: 14576665 DOI: 10.1067/S0190]
150. Chiu YC, Tai WC, Chuah SK, Hsu PI, Wu DC, Wu KL, Huang CC, Ho JC, Ring J, Chen WC. The Clinical Correlations of Helicobacter pylori Virulence Factors and Chronic Spontaneous Urticaria. Gastroenterol Res Pract 2013; 2013: 436727 [PMID: 23956739 DOI: 10.1155/2013/436727]
151. Campanati A, Gesuita R, Giannoni M, Piraccini F, Sandroni L, Martina E, Conocchiari L, Bendia E, Di Sario A, Offidani A. Role of small intestinal bacterial overgrowth and Helicobacter pylori infection in chronic spontaneous urticaria: a prospective analysis. Acta Derm Venereol 2013; 93: 161-164 [PMID: 22858910 DOI: 10.2340/00015555-1373]
152. Yoshimasu T, Furukawa F. Eradication therapy for urticaria with high titers of anti H. pylori IgG antibody. Allergol Int 2014; 63: 37-40 [PMID: 24270226 DOI: 10.2332/allergolint.13-OA-0580]
153. Ali M, Whitehead M. Clearance of chronic psoriasis after eradication therapy for Helicobacter pylori infection. J Eur Acad Dermatol Venereol 2008; 22: 753-754 [PMID: 18005018 DOI: 10.1111/j.1468-3083.2007.02452.x]
154. Martin Hübner A, Tenbaum SP. Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: a case report. Clin Exp Dermatol 2008; 33: 339-340 [PMID: 18201263 DOI: 10.1111/j.1365-2230.2007.02634.x]
155. Onsun N, Arda Ulusal H, Su O, Beycan I, Biyik Ozkaya D, Senocak M. Impact of Helicobacter pylori infection on severity of psoriasis and response to treatment. Eur J Dermatol 2012; 22: 117-120 [PMID: 22063790 DOI: 10.1684/ejd.2011.1579]
156. Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007; 110: 695-703 [PMID: 17766620 DOI: 10.1097/01.AOG.0000278571.93861.26]
157. Guven MA, Ertas IE, Coskun A, Ciragil P. Serologic and stool antigen assay of Helicobacter pylori infection in hyperemesis gravidarum: which test is useful during early pregnancy? Taiwan J Obstet Gynecol 2011; 50: 37-41 [PMID: 21482373 DOI: 10.1016/j.tjog.2009.11.003]
158. Mansour GM, Nashaat EH. Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum. Arch Gynecol Obstet 2011; 284: 843-847 [PMID: 21079980 DOI: 10.1007/s00404-010-1759-8]
159. Cardaropoli S, Rolfo A, Piazzese A, Ponzetto A, Todros T. Helicobacter pylori's virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J Gastroenterol 2011; 17: 5156-5165 [PMID: 22215939 DOI: 10.3748/wjg.v17.i47.5156]
160. Franceschi F, Di Simone N, D'Ippolito S, Castellani R, Di Nicuolo F, Gasbarrini G, Yamaoka Y, Todros T, Scambia G, Gasbarrini A. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia? Helicobacter 2012; 17: 426-434 [PMID: 23066738 DOI: 10.1111/j.1523-5378.2012.00966.x]
161. Bai X, Wang D, Fan Z, Han Y, Xu L, Zhang G, Lu S, Liu W, Li J, Wang H. Helicobacter pylori may cause otitis media with effusion: a pilot study. B-ENT 2012; 8: 261-264 [PMID: 23409554]
162. Iriz A, Eryilmaz A, Gocer C, Acar A, Boynuegri S, Dursun E. Could Helicobacter pylori play a role in the aetiopathogenesis of tympanosclerosis? J Laryngol Otol 2011; 125: 1121-1124 [PMID: 21888743 DOI: 10.1017/S0022215111002301]
163. Park CW, Chung JH, Min HJ, Kim KR, Tae K, Cho SH, Lee SH. Helicobacter pylori in middle ear of children with otitis media with effusion. Chin Med J (Engl) 2011; 124: 4275-4278 [PMID: 22340399]
164. Melake NA, Shaker GH, Salama MA. Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies. Saudi Pharm J 2012; 20: 345-353 [PMID: 23960809 DOI: 10.1016/j.jsps.2012.02.004]
165. Kraus J, Nártová E, Pavlík E, Katra R, Sterzl I, Astl J. Prevalence of Helicobacter pylori in adenotonsillar hypertrophy in children. Acta Otolaryngol 2014; 134: 88-92 [PMID: 24256044 DOI: 10.3109/00016489.2013.840924]
166. Aycicek A, Çetinkaya Z, Kiyici H, Bukulmez A, Yucedag F. Can Helicobacter pylori cause inflammation in the middle ear? Int J Pediatr Otorhinolaryngol 2012; 76: 1087-1090 [PMID: 22552023 DOI: 10.1016/j.ijporl.2012.04.005]
167. Cvorovic L, Brajovic D, Strbac M, Milutinovic Z, Cvorovic V. Detection of Helicobacter pylori in nasal polyps: preliminary report. J Otolaryngol Head Neck Surg 2008; 37: 192-195 [PMID: 19128611]
168. Včeva A, Danić D, Včev A, Birtić D, Mihalj H, Zubčić Z, Kotromanović Z, Danić Hadžibegović A. The significance of Helicobacter pylori in patients with nasal polyposis. Med Glas (Zenica) 2012; 9: 281-286 [PMID: 22926364]
169. Jelavic B, Grgić M, Cupić H, Kordić M, Vasilj M, Baudoin T. Prognostic value of Helicobacter pylori sinonasal colonization for efficacy of endoscopic sinus surgery. Eur Arch Otorhinolaryngol 2012; 269: 2197-2202 [PMID: 22237763 DOI: 10.1007/s00405-012-1923-9]
170. Koc C, Arikan OK, Atasoy P, Aksoy A. Prevalence of Helicobacter pylori in patients with nasal polyps: a preliminary report. Laryngoscope 2004; 114: 1941-1944 [PMID: 15510018 DOI: 10.1097/01.mlg.0000147924.96980.34]
171. Burduk PK, Kaczmarek A, Budzynska A, Kazmierczak W, Gospodarek E. Detection of Helicobacter pylori and cagA gene in nasal polyps and benign laryngeal diseases. Arch Med Res 2011; 42: 686-689 [PMID: 22222490 DOI: 10.1016/j.arcmed.2011.12.005]
172. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119: 1149-1158 [PMID: 23303625 DOI: 10.1002/cncr.27834]
173. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, Shao L, Zou DH, Yu XM, Mao WM. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19: 6098-6107 [PMID: 24106412 DOI: 10.3748/wjg.v19.i36.6098]
174. Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, Sakaguchi Y, Nakayama C, Konno-Shimizu M, Matsuda R, Mochizuki S, Asada-Hirayama I, Tsuji Y, Kodashima S, Ono S, Niimi K, Mitsushima T, Koike K. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One 2013; 8: e69891 [PMID: 23922844 DOI: 10.1371/journal.pone.0069891]
175. Xinias I, Maris T, Mavroudi A, Panteliadis C, Vandenplas Y. Helicobacter pylori infection has no impact on manometric and pH-metric findings in adolescents and young adults with gastroesophageal reflux and antral gastritis: eradication results to no significant clinical improvement. Pediatr Rep 2013; 5: e3 [PMID: 23667732 DOI: 10.4081/pr.2013.e3]
176. Rodrigues Jr L, Faria CM, Geocze S, Chehter L. Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, openlabel, controlled trial. Arq Gastroenterol 2012; 49: 56-63 [PMID: 22481687]
177. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-147, 1413-147, [PMID: 17997357]
178. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014; 12: 239-245 [PMID: 23988686 DOI: 10.1016/j.cgh.2013.08.029]
179. Thrift AP, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol 2012; 2: 11 [PMID: 22655259 DOI: 10.3389/fonc.2012.00011]
180. Zullo A, Hassan C, Repici A, Bruzzese V. Helicobacter pylori eradication and reflux disease onset: did gastric acid get "crazy"? World J Gastroenterol 2013; 19: 786-789 [PMID: 23429673 DOI: 10.3748/wjg.v19.i6.786]
181. McColl KE. Helicobacter pylori and oesophageal cancer - not always protective. Gut 2007; 56: 457-459 [PMID: 17369378 DOI: 10.1136/gut.2006.111385]
182. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, Rakhshani N, Didevar R, Sotoudeh M, Zolfeghari AA, McColl KE. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008; 57: 298-305 [PMID: 17965056 DOI: 10.1136/gut.2007.137364]
183. Lee YY, Mahendra Raj S, Graham DY. Helicobacter pylori infection - a boon or a bane: lessons from studies in a lowprevalence population. Helicobacter 2013; 18: 338-346 [PMID: 23607896 DOI: 10.1111/hel.12058]
184. Tian XF, Fan XG, Zhang Y, Huang Y, Dai H, Ying RS. Procuration and identification of bacteria in paraffin-embedded liver tissues of hepatocellular carcinoma by laser-assisted microdissection technique. APMIS 2008; 116: 10-15 [PMID: 18254774 DOI: 10.1111/j.1600-0463.2008.00739.x]
185. Ward JM, Anver MR, Haines DC, Benveniste RE. Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 1994; 145: 959-968 [PMID: 7943185]
186. Kosaka T, Tajima Y, Kuroki T, Mishima T, Adachi T, Tsuneoka N, Fukuda K, Kanematsu T. Helicobacter bilis colonization of the biliary system in patients with pancreaticobiliary maljunction. Br J Surg 2010; 97: 544-549 [PMID: 20155791 DOI: 10.1002/bjs.6907]
187. Ilvan A, Ozturkeri H, Capraz F, Cermik H, Kunter E. Investigation of Helicobacter pylori in bronchoscopic lung specimens of young male patients with bronchiectasis but without gastrointestinal symptoms. Clin Microbiol Infect 2004; 10: 257-260 [PMID: 15008949]
188. Tsang KW, Lam SK, Lam WK, Karlberg J, Wong BC, Hu WH, Yew WW, Ip MS. High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med 1998; 158: 1047-1051 [PMID: 9769259 DOI: 10.1164/ajrccm.158.4.9712104]
189. Roussos A, Philippou N, Krietsepi V, Anastasakou E, Alepopoulou D, Koursarakos P, Iliopoulos I, Gourgoulianis K. Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease. Respir Med 2005; 99: 279-284 [PMID: 15733502 DOI: 10.1016/j.rmed.2004.08.007]
190. Prónai L, Schandl L, Orosz Z, Magyar P, Tulassay Z. Lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - antibiotic use in the history does not play a significant role. Helicobacter 2004; 9: 278-283 [PMID: 15165265 DOI: 10.1111/j.1083-4389.2004.00223.x]
191. Behrendt CE. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128: 1239-1244 [PMID: 16162712]
192. Kountouras J, Mylopoulos N, Chatzopoulos D, Zavos C, Boura P, Konstas AG, Venizelos J. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med 2002; 162: 1237-1244 [PMID: 12038941]
193. Galloway PH, Warner SJ, Morshed MG, Mikelberg FS. Helicobacter pylori infection and the risk for open-angle glaucoma. Ophthalmology 2003; 110: 922-925 [PMID: 12750090 DOI: 10.1016/S0161-6420(03)00093-9]
194. Kurtz S, Regenbogen M, Goldiner I, Horowitz N, Moshkowitz M. No association between Helicobacter pylori infection or CagA-bearing strains and glaucoma. J Glaucoma 2008; 17: 223-226 [PMID: 18414109 DOI: 10.1097/IJG.0b013e31815a34ac]
195. Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo) 2012; 67: 1047-1052 [PMID: 23018302 DOI: 10.6061/clinics/2012(09)11]
196. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011; 17: 99-103 [PMID: 21245962]
197. Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y. The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther Clin Risk Manag 2013; 9: 355-360 [PMID: 24043941 DOI: 10.2147/TCRM.S50407]
198. Niehues M, Hensel A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J Pharm Pharmacol 2009; 61: 1303-1307 [PMID: 19814861 DOI: 10.1211/jpp/61.10.0005]
199. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66: 1824-1829 [PMID: 16801644 DOI: 10.1212/01.wnl.0000221672.01272.ba]
200. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009; 29: 379-386 [PMID: 19053985 DOI: 10.1111/j.1365-2036.2008.03906.x]
201. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008; 23: 1696-1700 [PMID: 18649391 DOI: 10.1002/mds.22190]
202. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013; 260: 2974-2980 [PMID: 24002418 DOI: 10.1007/s00415-013-7089-6]
203. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012; 19: 864-869 [PMID: 22248366 DOI: 10.1111/j.1468-1331.2011.03643.x]
204. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter 2010; 15: 279-294 [PMID: 20633189 DOI: 10.1111/j.1523-5378.2010.00768.x]
205. Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, Weller C, Bjarnason I, Charlett A, Lawson AJ, Dobbs RJ, Dobbs SM, Haesebrouck F. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther 2013; 38: 1347-1353 [PMID: 24117797 DOI: 10.1111/apt.12520]
206. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, Tsolaki M, Chatzopoulos D, Katsinelos P, Tzilves D, Zabouri A, Michailidou I. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci 2009; 119: 765-777 [PMID: 19326283 DOI: 10.1080/00207450902782083]
207. Malaguarnera M, Bella R, Alagona G, Ferri R, Carnemolla A, Pennisi G. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med 2004; 15: 381-386 [PMID: 15522573 DOI: 10.1016/j.ejim.2004.05.008]
208. Shiota S, Murakami K, Yoshiiwa A, Yamamoto K, Ohno S, Kuroda A, Mizukami K, Hanada K, Okimoto T, Kodama M, Abe K, Yamaoka Y, Fujioka T. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol 2011; 258: 1460-1463 [PMID: 21336779 DOI: 10.1007/s00415-011-5957-5]
209. Beydoun MA, Beydoun HA, Shroff MR, Kitner-Triolo MH, Zonderman AB. Helicobacter pylori seropositivity and cognitive performance among US adults: evidence from a large national survey. Psychosom Med 2013; 75: 486-496 [PMID: 23697465 DOI: 10.1097/PSY.0b013e31829108c3]
210. Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, Tzilves D, Katsinelos P, Tsolaki M, Chatzopoulos D, Venizelos I. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 2009; 256: 758-767 [PMID: 19240960 DOI: 10.1007/s00415-009-5011-z]
211. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Chatzigeorgiou S, Katsinelos P, Grigoriadis N, Giartza-Taxidou E, Venizelos I. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol 2010; 23: 199-204 [PMID: 20829670 DOI: 10.1097/WNN.0b013e3181df3034]
212. Ge R, Sun X, Wang D, Zhou Q, Sun H. Histidine-rich protein Hpn from Helicobacter pylori forms amyloid-like fibrils in vitro and inhibits the proliferation of gastric epithelial AGS cells. Biochim Biophys Acta 2011; 1813: 1422-1427 [PMID: 21539864 DOI: 10.1016/j.bbamcr.2011.04.005]
213. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996; 41: 458-461 [PMID: 8617115]
214. Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract 2013; 99: 200-208 [PMID: 23395214 DOI: 10.1016/j.diabres.2012.11.012]
215. Sathyaprakash R, Henry RR. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep 2002; 2: 416-422 [PMID: 12643167]
216. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008; 103: 3005-3010 [PMID: 19086952 DOI: 10.1111/j.1572-0241.2008.02151.x]
217. Chung GE, Heo NJ, Park MJ, Chung SJ, Kang HY, Kang SJ. Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria. World J Gastroenterol 2013; 19: 97-102 [PMID: 23326169 DOI: 10.3748/wjg.v19.i1.97]
218. Ibrahim A, Zaher T, Ghonemy TA, El-Azim SA, El-Azim MA, Ramadan A. Impact of cytotoxin-associated gene A of Helicobacter pylori strains on microalbuminuria in type 2 diabetes. Saudi J Kidney Dis Transpl 2010; 21: 694-700 [PMID: 20587874]
219. Agrawal RP, Sharma R, Garg D, Pokharna R, Kochar DK, Kothari RP. Role of Helicobacter pylori in causation of diabetic gastropathies and non-gastrointestinal complications in type 2 diabetes. J Indian Med Assoc 2010; 108: 140-143 [PMID: 21043350]
220. Wang F, Fu Y, Lv Z. Association of Helicobacter pylori infection with diabetic complications: a meta-analysis. Endocr Res 2014; 39: 7-12 [PMID: 23879556 DOI: 10.3109/07435800.2013.794426]
221. El-Eshmawy MM, El-Hawary AK, Abdel Gawad SS, El-Baiomy AA. Helicobacter pylori infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. Diabetol Metab Syndr 2011; 3: 28 [PMID: 22029731 DOI: 10.1186/1758-5996-3-28]
222. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013; 36: 166-175 [PMID: 23264288 DOI: 10.2337/dc12-0702]
223. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520-525 [PMID: 22279028 DOI: 10.2337/dc11-1043]
224. Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis 2012; 205: 1195-1202 [PMID: 22427676 DOI: 10.1093/infdis/jis106]
225. Akanuma M, Yanai A, Sakamoto K, Hirata Y, Yamaji Y, Kawazu S, Maeda S. Influence of Helicobacter pylori eradication on the management of type 2 diabetes. Hepatogastroenterology 2012; 59: 641-645 [PMID: 22328266 DOI: 10.5754/hge11960]
226. Bassaganya-Riera J, Dominguez-Bello MG, Kronsteiner B, Carbo A, Lu P, Viladomiu M, Pedragosa M, Zhang X, Sobral BW, Mane SP, Mohapatra SK, Horne WT, Guri AJ, Groeschl M, Lopez-Velasco G, Hontecillas R. Helicobacter pylori colonization ameliorates glucose homeostasis in mice through a PPAR γ-dependent mechanism. PLoS One 2012; 7: e50069 [PMID: 23166823 DOI: 10.1371/journal.pone.0050069]
227. Ataseven H, Demir M, Gen R. Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus. South Med J 2010; 103: 988-992 [PMID: 20818305 DOI: 10.1097/SMJ.0b013e3181eea6cc]
228. Boltin D, Niv Y. Ghrelin, Helicobacter pylori and body mass: is there an association? Isr Med Assoc J 2012; 14: 130-132 [PMID: 22693798]
229. Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 922-929 [PMID: 21366634 DOI: 10.1111/j.1365-2036.2011.04610.x]
230. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-439 [PMID: 8011406]
231. Khodaii Z, Vakili H, Ghaderian SM, Najar RA, Panah AS. Association of Helicobacter pylori infection with acute myocardial infarction. Coron Artery Dis 2011; 22: 6-11 [PMID: 20962628 DOI: 10.1097/MCA.0b013e3283402360]
232. Mayr M, Kiechl S, Mendall MA, Willeit J, Wick G, Xu Q. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003; 34: 610-615 [PMID: 12624280 DOI: 10.1161/01.STR.0000058481.82639.EF]
233. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-1679 [PMID: 9591760]
234. Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konturek SJ. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol 1999; 50: 743-751 [PMID: 10695556]
235. Niccoli G, Franceschi F, Cosentino N, Giupponi B, De Marco G, Merra G, Conte M, Montone RA, Ferrante G, Bacà M, Gasbarrini A, Silveri NG, Crea F. Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis 2010; 21: 217-221 [PMID: 20389238 DOI: 10.1097/MCA.0b013e3283399f36]
236. Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D, Lanza GA, Gasbarrini G, Gentiloni SN, Crea F. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 2009; 202: 535-542 [PMID: 18599062 DOI: 10.1016/j.atherosclerosis.2008.04.051]
237. Rasmi Y, Raeisi S, Seyyed Mohammadzad MH. Association of inflammation and cytotoxin-associated gene a positive strains of helicobacter pylori in cardiac syndrome x. Helicobacter 2012; 17: 116-120 [PMID: 22404441 DOI: 10.1111/j.1523-5378.2011.00923.x]
238. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; 142: 207-210 [PMID: 9920523 DOI: 10.1016/S0021-9150(98)00194-4]
239. Chimienti G, Russo F, Lamanuzzi BL, Nardulli M, Messa C, Di Leo A, Correale M, Giannuzzi V, Pepe G. Helicobacter pylori is associated with modified lipid profile: impact on Lipoprotein(a). Clin Biochem 2003; 36: 359-365 [PMID: 12849867 DOI: 10.1016/S0009-9120(03)00063-8]
240. Satoh H, Saijo Y, Yoshioka E, Tsutsui H. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 2010; 17: 1041-1048 [PMID: 20610892 DOI: 10.5551/jat.5157]
241. Kucukazman M, Yavuz B, Sacikara M, Asilturk Z, Ata N, Ertugrul DT, Yalcin AA, Yenigun EC, Kizilca G, Okten H, Akin KO, Nazligul Y. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci 2009; 54: 604-607 [PMID: 18649137 DOI: 10.1007/s10620-008-0391-y]
242. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010; 103: 190-196 [PMID: 20134372 DOI: 10.1097/SMJ.0b013e3181cf373f]
243. Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioʇlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 2005; 50: 1228-1231 [PMID: 16047464]
244. Akbas HS, Basyigit S, Suleymanlar I, Kemaloglu D, Koc S, Davran F, Demir I, Suleymanlar G. The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. Lipids Health Dis 2010; 9: 92 [PMID: 20804546 DOI: 10.1186/1476-511X-9-92]
245. Sawayama Y, Hamada M, Otaguro S, Maeda S, Ohnishi H, Fujimoto Y, Taira Y, Hayashi J. Chronic Helicobacter pylori infection is associated with peripheral arterial disease. J Infect Chemother 2008; 14: 250-254 [PMID: 18574664 DOI: 10.1007/s10156-008-0613-4]
246. McDonagh TA, Woodward M, Morrison CE, McMurray JJ, Tunstall-Pedoe H, Lowe GD, McColl KE, Dargie HJ. Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J 1997; 18: 1257-1260 [PMID: 9458417]
247. Manolakis A, Kapsoritakis AN, Potamianos SP. A review of the postulated mechanisms concerning the association of Helicobacter pylori with ischemic heart disease. Helicobacter 2007; 12: 287-297 [PMID: 17669100 DOI: 10.1111/j.1523-5378.2007.00511.x]
248. Carter AM, Moayyedi P, Catto A, Heppell RM, Axon AT, Grant PJ. The influence of Helicobacter pylori status on circulating levels of the coagulation factors fibrinogen, von Willebrand factor, factor VII, and factor VIII. Helicobacter 1996; 1: 65-69 [PMID: 9398916]
249. Shi WJ, Liu W, Zhou XY, Ye F, Zhang GX. Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid 2013; 23: 1294-1300 [PMID: 23544831 DOI: 10.1089/thy.2012.0630]
250. Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and Helicobacter pylori: the correlation is present only in Graves's disease. World J Gastroenterol 2012; 18: 1093-1097 [PMID: 22416184 DOI: 10.3748/wjg.v18.i10.1093]
251. Wang Y, Zhu S, Xu Y, Wang X, Zhu Y. Interaction between gene A-positive Helicobacter pylori and human leukocyte antigen II alleles increase the risk of Graves disease in Chinese Han population: an association study. Gene 2013; 531: 84-89 [PMID: 23954255 DOI: 10.1016/j.gene.2013.07.069]
252. Bassi V, Santinelli C, Iengo A, Romano C. Identification of a correlation between Helicobacter pylori infection and Graves' disease. Helicobacter 2010; 15: 558-562 [PMID: 21073613 DOI: 10.1111/j.1523-5378.2010.00802.x]
253. Bertalot G, Montresor G, Tampieri M, Spasiano A, Pedroni M, Milanesi B, Favret M, Manca N, Negrini R. Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin Endocrinol (Oxf) 2004; 61: 650-652 [PMID: 15521972]
254. Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter 2011; 16: 124-130 [PMID: 21435090 DOI: 10.1111/j.1523-5378.2011.00830.x]
255. Shen Z, Qin Y, Liu Y, Lu Y, Munker S, Chen L, Yu C, Chen P, Li Y. Helicobacter pylori infection is associated with the presence of thyroid nodules in the euthyroid population. PLoS One 2013; 8: e80042 [PMID: 24244604 DOI: 10.1371/journal.pone.0080042]
256. Danese S, Zoli A, Cremonini F, Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol 2000; 27: 1568-1569 [PMID: 10852299]
257. Farina G, Rosato E, Francia C, Proietti M, Donato G, Ammendolea C, Pisarri S, Salsano F. High incidence of Helicobacter pylori infection in patients with systemic sclerosis: association with Sicca Syndrome. Int J Immunopathol Pharmacol 2001; 14: 81-85 [PMID: 12604022]
258. Yazawa N, Fujimoto M, Kikuchi K, Kubo M, Ihn H, Sato S, Tamaki T, Tamaki K. High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J Rheumatol 1998; 25: 650-653 [PMID: 9558164]
259. Radić M, Kaliterna DM, Bonacin D, Vergles JM, Radić J, Fabijanić D, Kovačić V. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int 2013; 33: 2943-2948 [PMID: 23224499 DOI: 10.1007/s00296-012-2585-z]
260. Reinauer S, Goerz G, Ruzicka T, Susanto F, Humfeld S, Reinauer H. Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication. Acta Derm Venereol 1994; 74: 361-363 [PMID: 7817672]
261. Mohebi N, Mamarabadi M, Moghaddasi M. Relation of helicobacter pylori infection and multiple sclerosis in Iranian patients. Neurol Int 2013; 5: 31-33 [PMID: 23888213 DOI: 10.4081/ni.2013.e10]
262. Li W, Minohara M, Su JJ, Matsuoka T, Osoegawa M, Ishizu T, Kira J. Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 2007; 184: 227-231 [PMID: 17296235 DOI: 10.1016/j.jneuroim.2006.12.010]
263. Barnett MH, Sutton I. Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol 2012; 25: 215-220 [PMID: 22487568 DOI: 10.1097/WCO.0b013e3283533a3f]
264. Li W, Minohara M, Piao H, Matsushita T, Masaki K, Matsuoka T, Isobe N, Su JJ, Ohyagi Y, Kira J. Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2009; 15: 1411-1421 [PMID: 19965522 DOI: 10.1177/1352458509348961]
265. Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, Kawano Y, Kira J. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 2013; 84: 29-34 [PMID: 23038741 DOI: 10.1136/jnnp-2012-302925]
266. Pezeshki MZ, Zarrintan S, Zarrintan MH. Helicobacter pylori nanoparticles as a potential treatment of conventional multiple sclerosis. Med Hypotheses 2008; 70: 1223 [PMID: 18242004 DOI: 10.1016/j.mehy.2007.12.008]
267. Chiba S, Sugiyama T, Matsumoto H, Hisano K, Awakawa T, Hiura K, Saitoh M, Imai K. Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain-Barré syndrome. Ann Neurol 1998; 44: 686-688 [PMID: 9778269 DOI: 10.1002/ana.410440416]
268. Ghabaee M, Ghanbarian D, Brujeni GN, Bokaei S, Siavoshi F, Gharibzadeh S. Could Helicobacter pylori play an important role in axonal type of Guillain-Barré syndrome pathogenesis? Clin Neurol Neurosurg 2010; 112: 193-198 [PMID: 20018440 DOI: 10.1016/j.clineuro.2009.11.008]
269. Kountouras J, Deretzi G, Zavos C, Karatzoglou P, Touloumis L, Nicolaides T, Chatzopoulos D, Venizelos I. Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2005; 12: 139-143 [PMID: 15679702 DOI: 10.1111/j.1468-1331.2004.00977.x]
270. Chiba S, Sugiyama T, Yonekura K, Tanaka S, Matsumoto H, Fujii N, Ebisu S, Sekiguchi K. An antibody to VacA of Helicobacter pylori in cerebrospinal fluid from patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2002; 73: 76-78 [PMID: 12082053]
271. Zhou X, Wu J, Zhang G. Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25: 460-468 [PMID: 23242126 DOI: 10.1097/MEG.0b013e32835c280a]
272. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, Müller A. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011; 121: 3088-3093 [PMID: 21737881 DOI: 10.1172/JCI45041]
273. Konturek PC, Rienecker H, Hahn EG, Raithel M. Helicobacter pylori as a protective factor against food allergy. Med Sci Monit 2008; 14: CR452-CR458 [PMID: 18758415]
274. Lebwohl B, Blaser MJ, Ludvigsson JF, Green PH, Rundle A, Sonnenberg A, Genta RM. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013; 178: 1721-1730 [PMID: 24124196 DOI: 10.1093/aje/kwt234]
275. Imamura S, Sugimoto M, Kanemasa K, Sumida Y, Okanoue T, Yoshikawa T, Yamaoka Y. Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese. J Gastroenterol Hepatol 2010; 25: 1244-1249 [PMID: 20594251 DOI: 10.1111/j.1440-1746.2010.06307.x]
276. Garn H, Neves JF, Blumberg RS, Renz H. Effect of barrier microbes on organ-based inflammation. J Allergy Clin Immunol 2013; 131: 1465-1478 [PMID: 23726530 DOI: 10.1016/j.jaci.2013.04.031]
277. Kaplan JL, Shi HN, Walker WA. The role of microbes in developmental immunologic programming. Pediatr Res 2011; 69: 465-472 [PMID: 21364495 DOI: 10.1203/PDR.0b013e318217638a]
278. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]
279. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
280. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22 [PMID: 11809181 DOI: 10.1016/S0140-6736(02)07273-2]
281. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979 [PMID: 9329511 DOI: 10.1016/S0140-6736(97)04523-6]
282. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005; 100: 453-459 [PMID: 15667507]
283. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94: 850-856 [PMID: 19483158 DOI: 10.3324/haematol.2008.005348]
284. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004; 20: 1001-1017 [PMID: 15569102]
285. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9: 347-368 [PMID: 15270750 DOI: 10.1111/j.1083-4389.2004.00235.x]
286. Vaira D, Malfertheiner P, Mégraud F, Axon AT, Deltenre M, Hirschl AM, Gasbarrini G, O'Morain C, Garcia JM, Quina M, Tytgat GN. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 1999; 354: 30-33 [PMID: 10406362]
287. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91: 1138-1144 [PMID: 8651160]
288. el-Zimaity HM. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol Clin North Am 2000; 29: 863-869 [PMID: 11190070]
289. van IJzendoorn MC, Laheij RJ, de Boer WA, Jansen JB. The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth J Med 2005; 63: 141-145 [PMID: 15869042]
290. Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. Gastroenterol Clin North Am 2000; 29: 871-878 [PMID: 11190071]
291. Li C, Ha T, Ferguson DA, Chi DS, Zhao R, Patel NR, Krishnaswamy G, Thomas E. A newly developed PCR assay of H. pylori in gastric biopsy, saliva, and feces. Evidence of high prevalence of H. pylori in saliva supports oral transmission. Dig Dis Sci 1996; 41: 2142-2149 [PMID: 8943965]
292. Makristathis A, Hirschl AM, Lehours P, Mégraud F. Diagnosis of Helicobacter pylori infection. Helicobacter 2004; 9 Suppl 1: 7-14 [PMID: 15347300 DOI: 10.1111/j.1083-4389.2004.00254.x]
293. Samarbaf-Zadeh AR, Tajbakhsh S, Moosavian SM, Sadeghi-Zadeh M, Azmi M, Hashemi J, Masjedi-Zadeh A. Application of fluorescent in situ hybridization (FISH) for the detection of Helicobacter pylori. Med Sci Monit 2006; 12: CR426-CR430 [PMID: 17006402]
294. Yilmaz O, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World J Gastroenterol 2007; 13: 671-675 [PMID: 17278188]
295. Morris JM, Reasonover AL, Bruce MG, Bruden DL, McMahon BJ, Sacco FD, Berg DE, Parkinson AJ. Evaluation of seaFAST, a rapid fluorescent in situ hybridization test, for detection of Helicobacter pylori and resistance to clarithromycin in paraffin-embedded biopsy sections. J Clin Microbiol 2005; 43: 3494-3496 [PMID: 16000488 DOI: 10.1128/JCM.43.7.3494-3496.2005]
296. Aktepe OC, Ciftc¸i IH, Safak B, Uslan I, Dilek FH. Five methods for detection of Helicobacter pylori in the Turkish population. World J Gastroenterol 2011; 17: 5172-5176 [PMID: 22215941 DOI: 10.3748/wjg.v17.i47.5172]
297. Miehlke S, Bayerdörffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin Gastrointest Dis 2001; 12: 167-179 [PMID: 11478749]
298. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-864 [PMID: 10383518]
299. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-379; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]
300. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-414 [PMID: 21188333]
301. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013; 19: 8168-8180 [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168]
302. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-1094 [PMID: 15207062 DOI: 10.3201/eid1006.030744]
303. Kim SY, Joo YM, Lee HS, Chung IS, Yoo YJ, Merrell DS, Cha JH. Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. J Antibiot (Tokyo) 2009; 62: 43-50 [PMID: 19132060 DOI: 10.1038/ja.2008.6]
304. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29: 389-396 [PMID: 17303392 DOI: 10.1016/j.ijantimicag.2006.11.007]
305. Xing JZ, Clarke C, Zhu L, Gabos S. Development of a microelectronic chip array for high-throughput genotyping of Helicobacter species and screening for antimicrobial resistance. J Biomol Screen 2005; 10: 235-245 [PMID: 15809319 DOI: 10.1177/1087057104273781]
306. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100 [PMID: 16418408 DOI: 10.7326/0003-4819-144-2-200601170-00006]
307. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357 [PMID: 17566020 DOI: 10.1038/gut.2007.125658]
308. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931 [PMID: 18490667 DOI: 10.1038/0000605-200806170-00226]
309. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106: 1970-1975 [PMID: 21989146 DOI: 10.1038/ajg.2011.306]
310. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700 [PMID: 11444467]
311. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35: 941-947 [PMID: 22372560 DOI: 10.1111/j.1365-2036.2012.05053.x]
312. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47: 25-32 [PMID: 23090045 DOI: 10.1097/MCG.0b013e318266f6cf]
313. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105: 445-453 [PMID: 24274441]
314. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]
315. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009; 29: 720-730 [PMID: 19183156 DOI: 10.1111/j.1365-2036.2009.03934.x]
316. de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, Rossi M, Marchi S. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007; 102: 951-956 [PMID: 17313499]